Based on ratings from 20 stock analysts, the Neurocrine Biosciences Inc stock price is expected to increase by 8.68% in 12 months. This is calculated by using the average 12-month stock price forecast for Neurocrine Biosciences Inc. The lowest target is $106.00 and the highest is $170.00. Please note analyst price targets are not guaranteed and could be missed completely.
NBIX is a stock in Health Care which has been forecasted to be worth $143.80 as an average. On the higher end, the forecast price is $170.00 USD by jay olson from Oppenheimer and on the lower end NBIX is forecasted to be $106.00 by david amsellem from Piper Sandler.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
anupam rama J.P. Morgan | Buy | None | maintained | Feb 13, 2024 |
yatin suneja Guggenheim | Buy | $164.0 | maintained | Feb 12, 2024 |
ami fadia Needham | Hold | None | rated | Feb 8, 2024 |
david amsellem Piper Sandler | Hold | $106.0 | reiterated | Feb 8, 2024 |
jay olson Oppenheimer | Buy | $170.0 | maintained | Feb 8, 2024 |
andrew fein H.C. Wainwright | Buy | $150.0 | maintained | Feb 8, 2024 |
brian skorney Robert W. Baird | Buy | $157.0 | maintained | Feb 7, 2024 |
tazeen ahmad Bank of America Securities | Buy | $154.0 | reiterated | Feb 7, 2024 |
neena bitritto garg Deutsche Bank | Buy | $161.0 | maintained | Feb 7, 2024 |
sumant kulkarni Canaccord Genuity | Buy | $154.0 | maintained | Feb 7, 2024 |
marc goodman Leerink Partners | Buy | $160.0 | maintained | Feb 7, 2024 |
david hoang Citi | Hold | $140.0 | maintained | Feb 7, 2024 |
laura chico Wedbush | Buy | $147.0 | maintained | Jan 29, 2024 |
paul matteis Stifel Nicolaus | Buy | $144.0 | maintained | Jan 26, 2024 |
chris shibutani Goldman Sachs | Buy | $153.0 | maintained | Jan 25, 2024 |
akash tewari Jefferies | Buy | $158.0 | maintained | Jan 18, 2024 |
evan seigerman BMO Capital | Hold | $116.0 | rated | Jan 10, 2024 |
brian abrahams RBC Capital | Hold | $129.0 | maintained | Jan 3, 2024 |
carter gould Barclays | Buy | $145.0 | maintained | Dec 18, 2023 |
mohit bansal Wells Fargo | Hold | $127.0 | maintained | Dec 12, 2023 |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
When did it IPO
1996
Staff Count
1,400
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Dr. Kevin C. Gorman Ph.D.
Market Cap
$13.17B
In 2023, NBIX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NBIX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
INCY-USD
$58.82
PODD-USD
$191.01
LKQ-USD
$50.04
FOXA-USD
$29.95
JKHY-USD
$173.1
GEN-USD
$21.55